CTLA4 and central nervous system cancer: We tested the drug response of gliomas to PD‐1 and CTLA‐4, and the results showed that high‐risk gliomas are highly responsive to PD‐1 immunotherapy, but poorly to CTLA‐4 immunotherapy.